Effect of Delapril/Manidipine vs Olmesartan/Hydrochlorothiazide Combination on Insulin Sensitivity and Fibrinogen in Obese Hypertensive Patients

Roberto Fogari, Giuseppe Derosa, Annalisa Zoppi, Pierangelo Lazzari, Luca Corradi, Paola Preti and Amedeo Mugellini

Abstract

Objective To compare the effect of delapril/manidipine vs olmesartan/hydrochlorothiazide (HCTZ) combination on insulin sensitivity and plasma fibrinogen in obese hypertensive patients.

Patients and Methods After a 4-week placebo period, 88 obese, hypertensive (DBP >95 and <110 mmHg) outpatients were randomized to delapril 30 mg/manidipine 10 mg combination or to olmesartan 20 mg/HCTZ 12.5 mg combination for 24 weeks according to a prospective, randomized, open-label, blinded endpoint, parallel group design. At the end of the placebo period and treatment period, clinical BP, fasting plasma glucose (FPG), plasma insulin, insulin sensitivity (by euglycemic hyperinsulinemic clamp) and plasma fibrinogen were evaluated. Insulin sensitivity was expressed as the amount of glucose infused during the last 30 minutes (glucose infusion rate, GIR) in mg/Kg/min. The total glucose requirement (TGR) to maintain a steady-state blood glucose level in response to a defined increase in plasma insulin concentration was also evaluated.

Results Both combinations significantly reduced SBP/DBP values (-22.3/16.4 mmHg and -22.6/17.2 mmHg, respectively, all p <0.001 vs placebo). GIR was significantly increased only by delapril/manidipine (+3.01 mg/min/Kg, p=0.038 vs placebo), the difference between treatments being significant (p <0.05). TGR was significantly increased by delapril/manidipine (+9.7 g, p=0.034), while it was unaffected by olmesartan/HCTZ. Plasma insulin as well as fibrinogen were significantly reduced by delapril/manidipine (-17.8 pmol/l, p=0.047 and -67.5 mg/dl, p=0.021, respectively), but not by olmesartan/HCTZ, the difference between the two treatments being statistically significant (p <0.05).

Conclusion In obese hypertensive patients the delapril/manidipine combination but not the olmesartan/HCTZ combination significantly decreased insulin resistance and plasma fibrinogen levels, despite the similar BP lowering efficacy.

Key words: hypertension, obesity, insulin-resistance, fibrinogen, delapril/manidipine


Introduction

The association between obesity and hypertension is well established: obese subjects have a 3.5-fold increased risk for developing hypertension and up to 60% of overweight or obese patients also have hypertension (1, 2). Insulin resistance with consequent hyperinsulinemia plays a pivotal role in the pathogenesis of obesity hypertension (3) and tends to cluster with glucose intolerance as well as with hemostatic and fibrinolytic disturbances, including high fibrinogen levels (4, 5). Endothelial dysfunction might be the pathogenetic link between these risk factors, whose clustering greatly accelerates the atherogenic process and its clinical complica-
tions (6, 7). Current hypertension treatment guidelines stress the role of total risk factor management and state the importance of not only lowering blood pressure (BP) values but also improving the global risk profile of hypertensive patients (8, 9). Thus optimal pharmacological treatment of obesity hypertension needs antihypertensive agents that do not exacerbate and possibly improve insulin resistance and the associated metabolic disturbances beyond lowering BP values (10-12). Furthermore, obesity is associated with the increased likelihood of not achieving goal BP: on a population basis, the probability of lack of BP control in obese hypertensives is about 50% higher than hypertensive patients who are at normal weight (13). Therefore, most obese hypertensives will require at least two antihypertensive agents to reach the BP goal of <140/90 mmHg and hypertension treatment guidelines encourage greater use of multidrug therapy especially in difficult to treat hypertension (8). Although no specific recommendation has been provided about the most effective combination antihypertensive strategy in obese hypertensives, ACE-inhibitors (ACE-I), angiotensin II receptor blockers (ARB) and calcium channel blockers (CCB), which are known to not adversely affect or even improve metabolic parameters (14-25) and diuretics, which counteract increased sodium and fluid retention and cardiac output typical or obesity hypertension (10-12), may all be suitable.

With this background the present study was undertaken to evaluate the effects on insulin sensitivity and plasma fibrinogen levels of the combination of the ACE-inhibitor delapril with the long-acting dihydropyridine calcium channel blocker manidipine as compared to the combination of the angiotensin receptor blocker olmesartan with hydrochlorothiazide in the treatment of obese hypertensive patients. We chose to test these drug combinations, at the usually recommended doses, since blockade of the renin angiotensin system with both an ACE inhibitor like delapril or an angiotensin receptor blocker like olmesartan is indicated in insulin resistant subjects like obese hypertensives. Also we wanted to verify whether adding to these agents a drug known to be metabolically neutral like manidipine or a drug known to exert potentially adverse metabolic effects like hydrochlorothiazide could differently influence insulin sensitivity and fibrinogen in these patients.

**Patients and Methods**

This was a prospective randomized, open-label, blinded endpoint (PROBE), parallel group study with two treatment arms.

The study population included 88 (46 men and 42 women) gender-matched obese [body mass index (BMI) ≥ 30 kg/m²; mean weight: 88.5 kg, range 78-112 kg], non smoking outpatients, aged 43-64 years (mean age: 55 years), with mild to moderate uncomplicated essential hypertension (DBP >95 and <110 mmHg). Out of 88 patients, 49 had never been previously treated for hypertension. Previously treated patients did not differ from those that were not medicated in terms of measured parameters. No gender difference in insulin sensitivity measures was observed. Patients with secondary forms of hypertension, diabetes mellitus, myocardial infarction or stroke within the previous 6 months, renal failure (serum creatinine >1.3 mg/dl), evidence of chronic liver disease, active peptic ulcer, pregnancy or lactation, major systemic diseases and any condition that would require the use of concomitant medication were excluded from the study. The study protocol was approved by the local Ethical Committee and written informed consent was obtained from each participant at the time of enrollment.

After an initial 4 weeks wash-out period with placebo, during which any eventual antihypertensive medication was discontinued, patients were randomly given delapril 30 mg/manidipine 10 mg combination o.d. or olmesartan 20 mg/HCTZ 12.5 mg combination o.d. for 24 weeks. From the time of enrollment until the completion of the study, each participant maintained his or her diet and usual level of physical activity and avoided a change in body weight. No concomitant medications were allowed.

At the end of the placebo and active-treatment period BP, insulin sensitivity and plasma fibrinogen were evaluated.

BP measurements were obtained from each patient (right arm) in the seated position, by using a standard mercury sphygmomanometer (Korotkoff I and V) with a cuff of appropriate size. Measurements were taken by the same doctor (not included in the study), blinded to treatment, in the morning before daily drug intake (i.e., about 24 hours after dosing) and after the subject had rested 10 minutes in a quiet room. Three successive BP readings were obtained at 1 minute intervals and averaged.

On the same day, 1 hour after the subjects had received their medication, insulin sensitivity was assessed by the euglycemic, hyperinsulinemic clamp, according to the technique of De Fronzo et al (26). At 9 a.m., after the subjects had fasted 12 hours overnight, an intravenous catheter was placed in an antecubital vein for infusion of insulin and 20% glucose. A second catheter was inserted into a brachial artery for blood sampling. A 10 minutes priming infusion of insulin (Actrapid HM, Novo Industries, Copenhagen, Denmark), calculated as the amount required to increase plasma insulin concentration to 100 U/ml during the insulin clamp, was followed by a constant infusion of 40 mU/min/m² of body surface area for 110 minutes. During insulin infusion, normal fasting blood glucose levels were maintained by adjustment of the infusion of a 20% glucose solution. The amount of glucose taken up (milligram per kilogram of body weight per minute) was calculated for each 10 minutes interval after the first 20 minutes of the clamp. Insulin sensitivity was calculated from the mean glucose uptake rate for the last 30 minutes of the clamp and expressed as the amount of glucose infused during that time (glucose infusion rate: GIR) in mg/kg/min. The total amount of exogenous glucose required to maintain a steady-state blood glu-
Inter Med 47: 361-366, 2008 DOI: 10.2169/internalmedicine.47.0449

Table 1. Mean Values of the Parameters at Baseline and after Treatment with Delapril/Manidipine and Olmesartan/HCTZ.

<table>
<thead>
<tr>
<th></th>
<th>Delapril/manidipine</th>
<th>Olmesartan/HCTZ</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline</td>
<td>Treatment</td>
<td>Baseline</td>
</tr>
<tr>
<td>n (M/F)</td>
<td>44 (24/20)</td>
<td>44 (24/20)</td>
</tr>
<tr>
<td>Age (y)</td>
<td>54±2.6</td>
<td>-</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>33.3±0.8</td>
<td>33.1±0.8</td>
</tr>
<tr>
<td>SBP (mmHg)</td>
<td>164.5±14.2</td>
<td>141.2±11.3</td>
</tr>
<tr>
<td>DBP (mmHg)</td>
<td>103.3±7.1</td>
<td>86.9±5.8</td>
</tr>
<tr>
<td>GIR (mg/min/kg)</td>
<td>4.89±0.39</td>
<td>7.78±0.52</td>
</tr>
<tr>
<td>TGR (g)</td>
<td>29.7±5.4</td>
<td>39.8±5.8</td>
</tr>
<tr>
<td>Insulin (pmol/L)</td>
<td>78.4±37.2</td>
<td>60.6±26.8</td>
</tr>
<tr>
<td>Glycemia (mg/dL)</td>
<td>94.6±6.4</td>
<td>91.1±5.9</td>
</tr>
<tr>
<td>Fibrinogen (mg/dL)</td>
<td>358.9±23.5</td>
<td>291.3±19.7</td>
</tr>
<tr>
<td>TC (mg/dL)</td>
<td>181.4±14.6</td>
<td>174.7±14.7</td>
</tr>
<tr>
<td>HDL-C (mg/dL)</td>
<td>45.9±2.3</td>
<td>46.4±2.8</td>
</tr>
<tr>
<td>TG (mg/dL)</td>
<td>134.7±35.6</td>
<td>121.6±31.2</td>
</tr>
</tbody>
</table>

BMI: body mass index, SBP: systolic blood pressure, DBP: diastolic blood pressure, GIR: glucose infusion rate, TGR: total glucose requirement, TC: total cholesterol, HDL-C: high-density lipoprotein-cholesterol, TG: triglycerides

* p < 0.05, ** p < 0.01, *** p < 0.001
+ p < 0.05 vs delapril/manidipine

glucose level in response to a defined increase in plasma insulin concentration (total glucose requirement: TGR) was also evaluated. Blood glucose in the fasting state and during glucose-clamp studies was measured by the glucose oxidase method (Beckman Auto-Analyzer; Fullerton, CA, USA). Plasma insulin concentrations were determined by radioimmunoassay (RIA).

Blood samples for evaluation of fibrinogen were drawn from an antecubital vein with minimal stasis after a 12 hours overnight fast and after N 10 minutes rest in the recumbent position. Fibrinogen levels were measured in citrated plasma samples by using a standard coagulation method (27). Fibrinogen measurements were performed in duplicate and averaged.

Metabolic parameters including total cholesterol (TC), high density lipoprotein cholesterol (HDLC) and total triglycerides (TG) as well as serum creatinine and body weight were measured at the end of the placebo and active treatment periods. Data are expressed as means ± standard deviations. The statistical analysis of the results was performed by analysis of variance (ANOVA) for repeated measures and Spearman’s rank correlation test. A p value <0.05 was considered statistically significant.

Results

All the 88 patients enrolled in the trial completed the study. Table 1 shows the main demographic and clinic characteristics of the two treatment groups at the end of the wash-out run-in period; there was no significant difference in gender distribution, age, BMI, BP values, TC, HDL-C, TG, fasting blood glucose, plasma insulin and fibrinogen levels. Duration of obesity-hypertension was similar in the two groups. The main results of the study are reported in Table 2.

Both delapril/manidipine combination and olmesartan/HCTZ combination significantly reduced SBP (by a mean of 22.3 mmHg, p<0.001 vs placebo and of 22.6 mmHg, p<0.001 vs placebo, respectively) with no statistical difference between the two treatments. HR was not significantly changed by any treatment.

During the euglycemic hyperinsulinemic clamp, plasma insulin levels increased acutely and remained at steady state plateau (mean value: 105.5 U/ml during placebo, 103.4 U/ml during delapril/manidipine and 106.1 U/ml during olmesartan/HCTZ). The mean rate of glucose uptake for the last 30 minutes of the clamp (GIR), considered as an index of insulin sensitivity, was significantly increased by delapril/manidipine combination (by a mean of 3.01 mg/min/kg, p=0.038 vs placebo), but not by olmesartan/HCTZ combination (-0.12 mg/min/kg, ns), the difference between the two active treatments being statistically significant (p<0.05). The total amount of exogenous glucose required to hold glucose level constant during the clamp (TGR) was not significantly modified by olmesartan/HCTZ as compared with placebo but was significantly increased by delapril/manidipine (+9.7 g, p=0.034 vs placebo): plasma insulin was significantly reduced by delapril/manidipine (by a mean of 17.8 pmol/l, p=0.047 vs placebo), but not by olmesartan/HCTZ combination. Plasma fibrinogen levels were significantly reduced by delapril/manidipine combination (by a mean of 65.5 mg/dl, p=0.021 vs placebo), but not by olmesartan/HCTZ (+4.3 mg/dl, ns), the difference between the two treatments being statistically significant (p<0.05). There was no significant change in body weight, BMI, fasting blood glucose, TC, HDL-C and TG during treatment with both delapril/manidipine and olmesartan/HCTZ (Table 2).
Table 2. Mean Values of SBP, DBP, GIR, TGR, Insulin, Glycaemia, Fibrinogen, TC, HDL-C, TG and BMI during Treatment with Delapril/manidipine and Olmesartan/HCTZ

<table>
<thead>
<tr>
<th></th>
<th>Delapril/manidipine</th>
<th>Olmesartan/HCTZ</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Baseline</td>
<td>Treatment</td>
</tr>
<tr>
<td>SBP (mmHg)</td>
<td>164.5±14.2</td>
<td>141.2±11.3</td>
</tr>
<tr>
<td>DBP (mmHg)</td>
<td>103.3±7.1</td>
<td>86.9±5.8</td>
</tr>
<tr>
<td>GIR (mg/min/Kg)</td>
<td>4.89±0.39</td>
<td>7.78±0.52</td>
</tr>
<tr>
<td>TGR (g)</td>
<td>29.7±5.4</td>
<td>39.8±5.8</td>
</tr>
<tr>
<td>Insulin (pmol/L)</td>
<td>78.4±37.2</td>
<td>60.6±26.8</td>
</tr>
<tr>
<td>Glycaemia (mg/dL)</td>
<td>94.4±6.4</td>
<td>91.1±5.9</td>
</tr>
<tr>
<td>Fibrinogen (mg/dL)</td>
<td>358.9±23.5</td>
<td>291.3±19.7</td>
</tr>
<tr>
<td>TC (mg/dL)</td>
<td>181.4±14.6</td>
<td>174.7±14.7</td>
</tr>
<tr>
<td>HDL-C (mg/dL)</td>
<td>45.9±2.3</td>
<td>46.4±2.8</td>
</tr>
<tr>
<td>TG (mg/dL)</td>
<td>134.7±35.6</td>
<td>121.6±31.2</td>
</tr>
<tr>
<td>BMI (Kg/m²)</td>
<td>33.3±0.8</td>
<td>33.1±0.8</td>
</tr>
</tbody>
</table>

GIR: glucose infusion rate, TGR: total glucose requirement, other abbreviation as in Table 1.

* p < 0.05, ** p < 0.01, *** p < 0.001
+ p < 0.05 vs delapril/manidipine

Discussion

The results of this study show that in obese patients with mild to moderate essential hypertension combination therapy with both delapril 30 mg plus manidipine 10 mg and olmesartan 20 mg plus HCTZ 12.5 mg was effective in significantly reducing SBP and DBP values, with no significant difference between the two treatments. This confirms the antihypertensive efficacy of these types of drug combination for the treatment of obesity hypertension.

The most interesting finding, however, is that, despite their equivalent BP lowering effect, delapril/manidipine combination produced a significant enhancement of insulin sensitivity and a decrease in fibrinogen concentrations whereas olmesartan/HCTZ combination did not influence insulin sensitivity nor fibrinogen levels.

The positive effect of delapril/manidipine combination on insulin sensitivity probably results from the combined action of the ACE-I and the CCB. ACE-I are well known to enhance insulin sensitivity (14-16, 18, 19) and have been demonstrated to decrease the risk for type 2 diabetes development (28-30). Mechanisms by which ACE-I improve insulin sensitivity include: a) blockade of Ang II induced vasoconstriction with consequent vasodilation and increased delivery of insulin and glucose to skeletal muscle (28, 29); b) reduced degradation of bradykinin, which exerts an insulin-like activity (31); the bradykinin mediated vasodilation with an increased capillary area and vascular permeability could also increase glucose and insulin delivery to tissue (32); c) increase in adiponectin and leptin levels, both of which enhance insulin sensitivity by promoting adipocyte differentiation (33); d) enhancement of the post-receptor activity of insulin (29) e) reduction in sympathetic tone via inhibition of Ang II (29); f) reduction of potentially toxic effects of Ang II within the pancreas, such as impaired pancreatic flow, islet cell fibrosis and death, cytokine release, oxidative stress, impaired first-phase insulin release (29). CCB are known to be metabolically neutral (23, 28) and some studies with long-acting dihydropyridine CCB, including manidipine, have reported that they can improve glucose tolerance and lower insulin levels (24, 25). Two mechanisms have been proposed for the reduction of insulin resistance that is seen with CCB (34, 35): first, these drugs produce vasodilation and enhance blood flow to skeletal muscle with consequent increased delivery of insulin and glucose and enhanced non-oxidative pathways of glucose utilization; secondly, CCB also improve insulin sensitivity at the cellular level by decreasing the cytosolic-free calcium concentrations.

The decreasing effect of delapril/manidipine combination on fibrinogen levels observed in the present study might be related mainly to the action of the ACE-I. While CCB have been generally reported to not significantly influence plasma fibrinogen concentrations (17, 36), clinical use of ACE-I has been associated with fibrinogen reduction (17-19, 37). Mechanisms for this decreasing effect are unclear: inhibition of some steps of the regulatory mechanisms which control the hepatic synthesis of fibrinogen with possible involvement of the kallikrein-kinin system has been suggested. Due to the relationships between insulin resistance and hemostatic and fibrinolytic disturbances, the variations of plasma fibrinogen concentrations might also be related to the ACE-I induced improvement in insulin sensitivity. Since no change in lipid parameters and BMI was observed during treatment with the delapril/manidipine combination, the reduction in fibrinogen concentrations seem unrelated to lipid profile or body weight modifications.

Although some controversial data have been initially reported in the literature, with some studies showing no effect on insulin resistance (18, 19, 38, 39), current opinion is that
ARB exert positive influence on insulin sensitivity (20-22, 40-43) and are also able to reduce the risk of onset of type 2 diabetes (28-30). ARB share the same mechanisms of insulin sensitivity improvement suggested for the ACE-I, with the exclusion of bradykinin mediated effects. Therefore, the lack of effect on insulin sensitivity observed in this study with olmesartan/HCTZ combination might be due to the influence of the diuretic. Thiazides are well known to enhance insulin resistance and worsen glycemic control although the mechanisms are unclear (40, 44-46). Proposed mechanisms include the effect of hypokalemia on insulin secretion (potassium depletion leads to impaired insulin release and a relative increase in the secretion of proinsulin, which is less biologically active), alterations in hepatic gluconeogenesis, an increase in free fatty acids, an increase in catecholamine release and a direct toxic effect on the pancreas (28, 44, 45). Thus, the possible negative effect of the diuretic on insulin sensitivity might have counteracted the potential beneficial effect of the ARB with a final neutral impact of the combination. Similar considerations might be valid also to explain the lack of effect of olmesartan/HCTZ combination on plasma fibrinogen concentrations. While ARB have been found to not affect (17-19) or to decrease plasma fibrinogen (47), thiazide diuretics have been reported to have no effect (17) or more frequently to increase fibrinogen concentrations (48).

From the clinical point of view, the question of whether changes in insulin sensitivity and fibrinogen levels may result in different degrees of protection from cardiovascular complications of hypertension remains unanswered to date. While waiting for specific data it seems reasonable to prefer drugs that do not worsen or even possibly improve these metabolic parameters, especially in high risk patients like obese hypertensives. In this regard delapril/mandipine combination seems to offer some advantage as compared to olmesartan/HCTZ combination.

In conclusion, with the limitation of the relatively small number of recruited patients, this study indicates that in the treatment of obese hypertensive patients, delapril/manidipine combination, but not olmesartan/HCTZ combination significantly increased insulin sensitivity and decreased plasma fibrinogen concentrations, despite the equivalent antihypertensive efficacy. Further large-scale studies are needed to confirm these results and to clarify whether the dual actions of lowering BP and reducing insulin resistance and fibrinogen levels might confer an advantage with regard to end-organ protection remains to be demonstrated.

References


© 2008 The Japanese Society of Internal Medicine
http://www.naika.or.jp/imindex.html